Inhibrx Biosciences Quarterly Income Statement
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences revenue and earnings
In the quarter ended Jun 30, 2026, Inhibrx Biosciences generated $0 in revenue, down 100.0% from the same quarter a year earlier. Inhibrx Biosciences reported a net loss of $36.6 million, compared with a loss of $28.7 million a year earlier. Diluted earnings per share came in at -$2.34.
Summary generated from market data by MetaCap's automated system. Methodology
Inhibrx Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | — | 0 | 0 | 1.30M | 0 | 100.00K | 0 | 100.00K | 0 | 1.63M | 119.00K |
| Revenue growth (YoY) | -100.00% | — | -100.00% | — | +1200.00% | — | -93.88% | -100.00% | +233.33% | — | — | — |
| Operating Expenses | 32.15M | 30.93M | 30.92M | 33.81M | 28.69M | 42.90M | 50.03M | 46.80M | 161.00M | 73.83M | 89.92M | 45.95M |
| Research & Development | 23.90M | 25.22M | 25.35M | 28.54M | 22.27M | 36.88M | 33.37M | 38.89M | 67.63M | 63.85M | 82.09M | 38.06M |
| Operating Income | -32.15M | -30.93M | -30.92M | -33.81M | -27.39M | -42.90M | -49.93M | -46.80M | -160.90M | -73.83M | -88.29M | -45.83M |
| Interest Expense | 5.69M | 3.51M | 3.19M | 3.18M | 3.14M | 2.69M | 0 | 0 | 5.36M | 8.13M | 8.22M | 8.15M |
| Other Income (Expense) | -4.50M | -2.51M | -1.91M | -1.44M | -1.26M | -410.00K | 2.06M | 2.93M | 2.02B | -4.88M | -3.69M | -5.96M |
| Pretax Income | -36.65M | -33.44M | -32.83M | -35.26M | -28.65M | -43.31M | -47.87M | -43.86M | 1.86B | -78.71M | — | -51.79M |
| Income Tax | 3.00K | 0 | 0 | 0 | 2.00K | 0 | 0 | 0 | 2.00K | 0 | -4.00K | 2.00K |
| Net Income | -36.65M | -33.44M | -32.83M | -35.26M | -28.65M | -43.31M | -47.87M | -43.86M | 1.86B | -78.71M | -93.60M | -51.79M |
| Net Income growth (YoY) | — | — | — | — | -101.54% | — | — | — | — | — | — | — |
| EPS (Basic) | -2.34 | -2.15 | -2.11 | -2.28 | -1.85 | -2.80 | -4.48 | -2.84 | 127.10 | -5.77 | — | -4.39 |
| EPS (Diluted) | -2.34 | -2.15 | -2.11 | -2.28 | -1.85 | -2.80 | -4.25 | -2.84 | 125.48 | -5.77 | — | -4.39 |
| Shares Outstanding (Basic) | 15.67M | 15.59M | — | 15.48M | 15.47M | 15.47M | — | 15.47M | 14.62M | 13.64M | — | 11.79M |
| Shares Outstanding (Diluted) | 15.67M | 15.59M | — | 15.48M | 15.47M | 15.47M | — | 15.47M | 14.81M | 13.64M | — | 11.79M |
| EBITDA | -31.63M | -30.39M | -30.36M | -33.23M | -26.73M | -42.23M | -49.24M | -46.04M | -160.42M | -73.47M | -87.99M | -45.52M |
| Operating Margin | — | — | — | — | -2106.85% | — | -49928.00% | — | -160898.00% | — | -5403.24% | -38510.08% |
| Net Margin | — | — | — | — | -2204.15% | — | -47865.00% | — | 1858011.00% | — | -5728.52% | -43520.17% |
This table shows 12 quarterly periods of Inhibrx Biosciences's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow INBX's reporting calendar. What is a income statement?